CA2385325A1 - Chlamydia antigens and corresponding dna fragments and uses thereof - Google Patents
Chlamydia antigens and corresponding dna fragments and uses thereof Download PDFInfo
- Publication number
- CA2385325A1 CA2385325A1 CA002385325A CA2385325A CA2385325A1 CA 2385325 A1 CA2385325 A1 CA 2385325A1 CA 002385325 A CA002385325 A CA 002385325A CA 2385325 A CA2385325 A CA 2385325A CA 2385325 A1 CA2385325 A1 CA 2385325A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- nucleic acid
- acid sequence
- seq
- immunoprotective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000606161 Chlamydia Species 0.000 title claims abstract 3
- 239000012634 fragment Substances 0.000 title claims 13
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 29
- 108020004707 nucleic acids Proteins 0.000 claims abstract 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract 14
- 239000002773 nucleotide Substances 0.000 claims abstract 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 3
- 229920001184 polypeptide Polymers 0.000 claims 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 229960005486 vaccine Drugs 0.000 claims 25
- 230000002480 immunoprotective effect Effects 0.000 claims 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000007190 Chlamydia Infections Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000013613 expression plasmid Substances 0.000 claims 1
- 101710116435 Outer membrane protein Proteins 0.000 abstract 4
- 241001647372 Chlamydia pneumoniae Species 0.000 abstract 1
- -1 DNA Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Abstract
The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infectio n by a strain of Chlamydia specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding OMP (outer membrane protein) of a strain ofChlamydia pneumoniae and a promoter to effect expression of the OMP (outer membrane protein) gene in the host. Modifications are possible within the scope of this invention.
Claims (18)
1. An immunoprotective vaccine which comprises a physiologically acceptable diluent or carrier suitable for use in a vaccine, and any one of:
(a) a first nucleic acid which encodes a first polypeptide;
(b) the first polypeptide;
(c) a fusion protein comprising the first polypeptide and a second polypeptide; or (d) a fusion nucleic acid encoding the fusion protein;
wherein the first polypeptide is selected from the group consisting of:
i) a polypeptide encoded by SEQ ID No: 1;
(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from SEQ ID NO: 1;
(iii) a polypeptide whose sequence is set forth in SEQ ID No: 2;
(iv) a polypeptide which is at least 75%
identical in amino acid sequence to SEQ ID No: 2;
(v) as immunogenic fragment comprising at least 12 consecutive amino acids from SEQ ID No:2; and (vi) a polypeptide as defined in (v) to (iv) or an immunogenic fragment as defined in (v) which has been modified without less of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (iv) or the corresponding fragment of (v); and wherein the first nucleic acid is capable of being expressed.
(a) a first nucleic acid which encodes a first polypeptide;
(b) the first polypeptide;
(c) a fusion protein comprising the first polypeptide and a second polypeptide; or (d) a fusion nucleic acid encoding the fusion protein;
wherein the first polypeptide is selected from the group consisting of:
i) a polypeptide encoded by SEQ ID No: 1;
(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from SEQ ID NO: 1;
(iii) a polypeptide whose sequence is set forth in SEQ ID No: 2;
(iv) a polypeptide which is at least 75%
identical in amino acid sequence to SEQ ID No: 2;
(v) as immunogenic fragment comprising at least 12 consecutive amino acids from SEQ ID No:2; and (vi) a polypeptide as defined in (v) to (iv) or an immunogenic fragment as defined in (v) which has been modified without less of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (iv) or the corresponding fragment of (v); and wherein the first nucleic acid is capable of being expressed.
2. The immunoprotective vaccine according to claim 1, wherein the vaccine comprises the first nucleic acid and a vaccine vector, and wherein the first nucleic acid is selected from the group consisting of:
(i) SEQ ID No: 1;
(ii) a nucleic acid sequence which encodes a polypeptide encoded by SEQ ID No: 1;
(iii) a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (i) and (ii);
(iv) a nucleic acid sequence which encodes a polypeptide which is at least 75% identical is amino acid sequence to the polypeptide encoded by SEQ ID No: 1;
(v) a nucleic acid sequence which encodes a polypeptide whose sequence is set forth in SEQ ID No: 2;
(vi) a nucleic acid sequence which encodes as immunogenic fragment comprising at least 12 consecutive amino acids from SEQ ID No:2; and (vii) a nucleic acid sequence which encodes a polypeptide as defined in (i) to (v) or an immunogenic fragment as defined in (vi) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (v) or the corresponding fragment of (vi).
(i) SEQ ID No: 1;
(ii) a nucleic acid sequence which encodes a polypeptide encoded by SEQ ID No: 1;
(iii) a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (i) and (ii);
(iv) a nucleic acid sequence which encodes a polypeptide which is at least 75% identical is amino acid sequence to the polypeptide encoded by SEQ ID No: 1;
(v) a nucleic acid sequence which encodes a polypeptide whose sequence is set forth in SEQ ID No: 2;
(vi) a nucleic acid sequence which encodes as immunogenic fragment comprising at least 12 consecutive amino acids from SEQ ID No:2; and (vii) a nucleic acid sequence which encodes a polypeptide as defined in (i) to (v) or an immunogenic fragment as defined in (vi) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (v) or the corresponding fragment of (vi).
3. The immunoprotective vaccine according to claim 1, wherein the vaccine comprises the fusion nucleic acid and a vaccine vector, and wherein the fusion nucleic acid comprises a first nucleic acid selected from the group consisting of:
(i) SEQ ID No: 1;
(ii) a nucleic acid sequence which encodes a polypeptide encoded by SEQ ID No: 1;
(iii) a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (i) and (ii);
(iv) a nucleic acid sequence which encodes a polypeptide which is at least 75% identical is amino acid sequence to the polypeptide encoded by SEQ ID NO: 1;
(v) a nucleic acid sequence which encodes a polypeptide whose sequence is set forth in SEQ ID No: 2;
(vi) a nucleic acid sequence which encodes an immunogenic fragment comprising at least 12 consecutive amino acids from SEQ ID No:2; and (vii) a nucleic acid sequence which encodes a polypeptide as defined in (i) to (v) or as immunogenic fragment as defined in (vi) which has been modified without lose of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (v) or the corresponding fragment of (vi).
(i) SEQ ID No: 1;
(ii) a nucleic acid sequence which encodes a polypeptide encoded by SEQ ID No: 1;
(iii) a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (i) and (ii);
(iv) a nucleic acid sequence which encodes a polypeptide which is at least 75% identical is amino acid sequence to the polypeptide encoded by SEQ ID NO: 1;
(v) a nucleic acid sequence which encodes a polypeptide whose sequence is set forth in SEQ ID No: 2;
(vi) a nucleic acid sequence which encodes an immunogenic fragment comprising at least 12 consecutive amino acids from SEQ ID No:2; and (vii) a nucleic acid sequence which encodes a polypeptide as defined in (i) to (v) or as immunogenic fragment as defined in (vi) which has been modified without lose of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (v) or the corresponding fragment of (vi).
4. The immunoprotective vaccine according to any one of claims 1 to 3, wherein the second polypeptide is a heterologous signal peptide.
5. The immunoprotective vaccine according to any one of claims 1 to 3, wherein the second polypeptide has adjuvant activity.
6. The immunoprotective vaccine according to any one of claims 1 to 5, wherein the first nucleic acid is operatively linked to one or more expression control sequences.
7. The immunoprotective vaccine according to any one of claims 1 to 6, wherein the first nucleic acid is expressed as a polypeptide, and wherein the vaccine comprises a second nucleic acid encoding as additional polypeptide which enhances the immune response to the polypeptide expressed by the first nucleic acid.
8. The immunoprotective vaccine according to claim 7, wherein the second nucleic acid encodes an additional Chlamydis polypeptide.
9. A pharmaceutical composition comprising the immunoprotective vaccine, according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier.
10. The immunoprotective vaccine according to claim 1, wherein the vaccine comprises the first polypeptide.
11. The immunoprotective vaccine according to claim 1, wherein the vaccine comprises the fusion protein.
12. The immunoprotective vaccine according to claim 11, wherein the second polypeptide is a heterologous signal peptide.
13. The immunoprotective vaccine according to claim 11, wherein the second polypeptide has adjuvant activity.
14. The immunoprotective vaccine according to any one of claims 10 to 13, further comprising an additional polypeptide which enhances the immune response to the first polypeptide.
15. The immunoprotective vaccine according to claim 14, wherein the additional polypeptide comprises a Chlamydia polypeptide.
16. A pharmaceutical composition comprising the immunoprotective vaccine according to any one of claims 10 to 15 and a pharmaceutically acceptable carrier.
17. Use for preventing or treating Chlamydia infection of an effective amount of the immunoprotective vaccine according to army one of claims 1 to 8 and 10 to 15.
18. Expression plasmid pCAmg002 as shown in Figure 3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15465299P | 1999-09-20 | 1999-09-20 | |
| US60/154,652 | 1999-09-20 | ||
| PCT/CA2000/001088 WO2001021804A1 (en) | 1999-09-20 | 2000-09-15 | Chlamydia antigens and corresponding dna fragments and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2385325A1 true CA2385325A1 (en) | 2001-03-29 |
| CA2385325C CA2385325C (en) | 2012-04-10 |
Family
ID=22552195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2385325A Expired - Fee Related CA2385325C (en) | 1999-09-20 | 2000-09-15 | Chlamydia antigens and corresponding dna fragments and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7314869B2 (en) |
| EP (1) | EP1220925B8 (en) |
| JP (1) | JP4667694B2 (en) |
| AT (1) | ATE384793T1 (en) |
| AU (1) | AU783547B2 (en) |
| CA (1) | CA2385325C (en) |
| DE (1) | DE60037900T2 (en) |
| NZ (1) | NZ517952A (en) |
| WO (1) | WO2001021804A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2340283A1 (en) | 1998-08-20 | 2000-03-02 | Aventis Pasteur Limited | Nucleic acid molecules encoding pomp91a protein of chlamydia |
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| EP1105490A1 (en) | 1998-08-20 | 2001-06-13 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
| US6649370B1 (en) | 1998-10-28 | 2003-11-18 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US6607730B1 (en) | 1998-11-02 | 2003-08-19 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| EP1135501A1 (en) | 1998-12-01 | 2001-09-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| AU772356B2 (en) * | 1998-12-04 | 2004-04-22 | Aventis Pasteur Limited | Two-step immunization procedure against chlamydia infection |
| EP2277892A3 (en) | 1998-12-08 | 2011-04-27 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| US7297341B1 (en) | 1998-12-23 | 2007-11-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| EP1140998B1 (en) | 1998-12-28 | 2008-01-23 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
| EP2172214A3 (en) | 1999-03-12 | 2011-03-16 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| AU780444B2 (en) | 1999-05-03 | 2005-03-24 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| JP4667694B2 (en) | 1999-09-20 | 2011-04-13 | サノフィ、パストゥール、リミテッド | Chlamydia antigen and corresponding DNA fragments and uses thereof |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| NZ520200A (en) * | 1999-12-22 | 2004-04-30 | Aventis Pasteur | Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product |
| ES2303525T3 (en) | 2000-04-21 | 2008-08-16 | Corixa Corporation | COMPOUNDS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF INFECTION BY CHLAMYDIA. |
| US6919187B2 (en) * | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| DE60125350T2 (en) | 2000-05-08 | 2007-07-12 | Sanofi Pasteur Ltd., Toronto | CHLAMYDIA ANTIGENES, CORRESPONDING DNA FRAGMENTS AND ITS USES |
| US20040005667A1 (en) | 2000-07-03 | 2004-01-08 | Giuloi Ratti | Immunisation against chlamydia pneumoniae |
| CN1906299A (en) * | 2003-11-21 | 2007-01-31 | 圣诺菲·帕斯图尔有限公司 | Immunization against chlamydia infection |
| CN102438650A (en) | 2009-03-06 | 2012-05-02 | 诺华有限公司 | Chlamydia antigens |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2259595C (en) | 1996-07-12 | 2010-11-30 | University Of Manitoba | Dna immunization against chlamydia infection |
| US6579854B1 (en) * | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
| DK1007685T3 (en) * | 1997-06-23 | 2006-08-14 | Loke Diagnostics Aps | Surface-exposed proteins from chlamydia pneumoniae |
| ATE352624T1 (en) * | 1997-11-21 | 2007-02-15 | Serono Genetics Inst Sa | CHLAMYDIA PNEUMONIAE GENOMIC SEQUENCES AND POLYPEPTIDES, FRAGMENTS AND APPLICATIONS THEREOF FOR DETECTION, PREVENTION AND CURE |
| DE69841894D1 (en) | 1997-11-21 | 2010-10-21 | Merck Serono Biodevelopment Sa | Outer membrane polypeptide of Chlamydia pneumoniae and fragments thereof and their use, in particular for the diagnosis, prevention and treatment of an infection |
| KR100769104B1 (en) | 1997-11-28 | 2007-10-23 | 세로노 제네틱스 인스티튜트 에스.에이. | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| EP1105490A1 (en) | 1998-08-20 | 2001-06-13 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
| US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| WO2000024765A2 (en) | 1998-10-28 | 2000-05-04 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| AU1722300A (en) | 1998-11-12 | 2000-05-29 | Regents Of The University Of California, The | Chlamydia pneumoniae genome sequence |
| US6822071B1 (en) | 1998-11-12 | 2004-11-23 | The Regents Of The University Of California | Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease |
| EP1135501A1 (en) | 1998-12-01 | 2001-09-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US6565856B1 (en) | 1998-12-08 | 2003-05-20 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| EP2277892A3 (en) | 1998-12-08 | 2011-04-27 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
| AU780444B2 (en) | 1999-05-03 | 2005-03-24 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| JP4667694B2 (en) | 1999-09-20 | 2011-04-13 | サノフィ、パストゥール、リミテッド | Chlamydia antigen and corresponding DNA fragments and uses thereof |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| WO2001046225A2 (en) | 1999-12-22 | 2001-06-28 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| NZ520200A (en) | 1999-12-22 | 2004-04-30 | Aventis Pasteur | Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product |
| US20020071831A1 (en) | 2000-04-04 | 2002-06-13 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020132994A1 (en) | 2000-04-04 | 2002-09-19 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020082402A1 (en) | 2000-04-04 | 2002-06-27 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020094965A1 (en) | 2000-04-04 | 2002-07-18 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20030100706A1 (en) | 2000-04-04 | 2003-05-29 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| ES2303525T3 (en) | 2000-04-21 | 2008-08-16 | Corixa Corporation | COMPOUNDS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF INFECTION BY CHLAMYDIA. |
| DE60125350T2 (en) | 2000-05-08 | 2007-07-12 | Sanofi Pasteur Ltd., Toronto | CHLAMYDIA ANTIGENES, CORRESPONDING DNA FRAGMENTS AND ITS USES |
| US20040254130A1 (en) | 2000-05-08 | 2004-12-16 | Murdin Andrew D | Chlamydia antigens and corresponding dna fragments and uses thereof |
| US20040005667A1 (en) | 2000-07-03 | 2004-01-08 | Giuloi Ratti | Immunisation against chlamydia pneumoniae |
-
2000
- 2000-09-15 JP JP2001525362A patent/JP4667694B2/en not_active Expired - Fee Related
- 2000-09-15 AT AT00962125T patent/ATE384793T1/en active
- 2000-09-15 EP EP00962125A patent/EP1220925B8/en not_active Expired - Lifetime
- 2000-09-15 DE DE60037900T patent/DE60037900T2/en not_active Expired - Lifetime
- 2000-09-15 AU AU73985/00A patent/AU783547B2/en not_active Ceased
- 2000-09-15 CA CA2385325A patent/CA2385325C/en not_active Expired - Fee Related
- 2000-09-15 WO PCT/CA2000/001088 patent/WO2001021804A1/en active IP Right Grant
- 2000-09-15 NZ NZ517952A patent/NZ517952A/en not_active IP Right Cessation
-
2003
- 2003-12-29 US US10/746,251 patent/US7314869B2/en not_active Expired - Fee Related
-
2005
- 2005-06-02 US US11/142,306 patent/US7662391B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1220925A1 (en) | 2002-07-10 |
| JP4667694B2 (en) | 2011-04-13 |
| EP1220925B1 (en) | 2008-01-23 |
| WO2001021804A1 (en) | 2001-03-29 |
| AU783547B2 (en) | 2005-11-10 |
| DE60037900D1 (en) | 2008-03-13 |
| US20050002944A1 (en) | 2005-01-06 |
| JP2003510050A (en) | 2003-03-18 |
| US7662391B2 (en) | 2010-02-16 |
| ATE384793T1 (en) | 2008-02-15 |
| AU7398500A (en) | 2001-04-24 |
| CA2385325C (en) | 2012-04-10 |
| EP1220925B8 (en) | 2008-04-23 |
| DE60037900T2 (en) | 2009-02-12 |
| WO2001021804B1 (en) | 2001-05-10 |
| US7314869B2 (en) | 2008-01-01 |
| US20050220805A1 (en) | 2005-10-06 |
| NZ517952A (en) | 2004-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2385325A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| CA2395499A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| US9346860B2 (en) | Expression system | |
| JP2002542827A5 (en) | ||
| WO2001021810B1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| JP2002537791A5 (en) | ||
| JP2003510050A5 (en) | ||
| RU2006105498A (en) | POLYEPEPTIDES FOR THE INDUCTION OF A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS | |
| JP2004502446A5 (en) | ||
| AU743165B2 (en) | Live attenuated bacteria of the species Actinobacillus pleuropneumoniae | |
| CA2365196A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| US6777202B2 (en) | Recombinant expression of S-layer proteins | |
| CA2327353A1 (en) | Structural proteins of fish pancreatic disease virus and uses thereof | |
| US7041792B2 (en) | Type F botulinum toxin and use thereof | |
| AU757762B2 (en) | Vaccines for chlamydia psittaci infections | |
| WO2002068662A8 (en) | Plasmid originated from bifidobacterium, recombinant expression vector using the plasmid and transformation method | |
| CA2223503A1 (en) | Transferrin receptor genes | |
| JP2004529601A5 (en) | ||
| JP2006514606A (en) | Hydrophobic protein expression | |
| WO1992003553A1 (en) | Footrot vaccine | |
| CA2069622A1 (en) | Vaccine | |
| AU2001269305B2 (en) | Expression system | |
| CA2345208A1 (en) | Protective recombinant haemophilus influenzae high molecular weight proteins | |
| JP2002541766A5 (en) | ||
| WO2001021805B1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150915 |